3,802 Shares in Gilead Sciences, Inc. $GILD Purchased by First Nebraska Trust Co

First Nebraska Trust Co bought a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the second quarter, Holdings Channel reports. The firm bought 3,802 shares of the biopharmaceutical company’s stock, valued at approximately $480,000.

Several other institutional investors also recently bought and sold shares of the company. BlackRock Inc. acquired a new stake in shares of Gilead Sciences during the second quarter worth about $15,393,785,000. Vanguard Group Inc. grew its holdings in shares of Gilead Sciences by 1.8% in the fourth quarter. Vanguard Group Inc. now owns 121,097,336 shares of the biopharmaceutical company’s stock valued at $14,863,487,000 after purchasing an additional 2,113,692 shares in the last quarter. State Street Corp grew its holdings in shares of Gilead Sciences by 1.9% in the fourth quarter. State Street Corp now owns 60,240,518 shares of the biopharmaceutical company’s stock valued at $7,393,921,000 after purchasing an additional 1,151,213 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in Gilead Sciences by 4.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 27,698,660 shares of the biopharmaceutical company’s stock worth $3,399,734,000 after buying an additional 1,195,269 shares during the period. Finally, Bank of America Corp DE increased its stake in Gilead Sciences by 15.2% during the 4th quarter. Bank of America Corp DE now owns 23,121,620 shares of the biopharmaceutical company’s stock worth $2,837,948,000 after buying an additional 3,046,688 shares during the period. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Price Performance

Shares of GILD opened at $146.12 on Friday. The firm has a market capitalization of $181.18 billion, a price-to-earnings ratio of -54.73 and a beta of 0.32. The firm’s fifty day simple moving average is $131.97 and its 200-day simple moving average is $136.59. Gilead Sciences, Inc. has a twelve month low of $108.46 and a twelve month high of $157.29. The company has a current ratio of 1.27, a quick ratio of 1.09 and a debt-to-equity ratio of 2.03.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) EPS for the quarter, topping analysts’ consensus estimates of ($7.25) by $0.50. The firm had revenue of $7.80 billion during the quarter, compared to the consensus estimate of $7.40 billion. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The company’s revenue was up 10.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.01 earnings per share. Equities analysts forecast that Gilead Sciences, Inc. will post -0.51 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th will be issued a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date of this dividend is Tuesday, September 15th. Gilead Sciences’s dividend payout ratio is -122.85%.

Wall Street Analyst Weigh In

GILD has been the subject of several recent research reports. Rothschild & Co Redburn decreased their price target on shares of Gilead Sciences from $170.00 to $167.00 in a research report on Monday, May 11th. Daiwa Securities Group cut their price objective on Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 19th. Barclays reduced their price objective on Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating on the stock in a research note on Wednesday, July 29th. Needham & Company LLC reiterated a “buy” rating and issued a $170.00 target price on shares of Gilead Sciences in a report on Wednesday, August 5th. Finally, Maxim Group raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 target price for the company in a research note on Wednesday, May 20th. Twenty-four analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $158.04.

Insiders Place Their Bets

In other news, CEO Daniel Patrick O’day sold 15,000 shares of the company’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $130.31, for a total value of $1,954,650.00. Following the completion of the transaction, the chief executive officer owned 592,133 shares in the company, valued at approximately $77,160,851.23. This represents a 2.47% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $145.02, for a total transaction of $725,100.00. Following the sale, the director owned 10,066 shares in the company, valued at $1,459,771.32. This represents a 33.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 87,000 shares of company stock valued at $11,562,960. 0.30% of the stock is owned by company insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.